AI Article Synopsis
- Elbow trauma can cause joint contracture and limit range of motion (ROM), with some cases requiring surgery, but full ROM is often not restored.
- Targeting myofibroblasts, which contribute to fibrotic tissue, could improve healing and ROM, with prior research showing that blebbistatin can inhibit their activity.
- In a study involving rats, while surgery improved outcomes initially, outcomes declined after three weeks and the addition of blebbistatin did not show significant benefits, leading to future research on its potential as a therapy for joint contracture.
Article Abstract
Elbow trauma can lead to joint contracture and reduced range of motion (ROM). Nonsurgical interventions can improve ROM, but in some cases capsule release surgery is required. Although surgery can improve ROM, it often does not restore full ROM. Thus, alternatives are needed. One approach is to target activated myofibroblasts, which are commonly associated with fibrotic tissue. Mechanical and biochemical cues drive a feedback loop that can result in normal or pathological healing. We hypothesize that this feedback loop exists in joint contracture and can be manipulated so that myofibroblast activity is reduced, normal healing is achieved, and ROM is improved. We previously demonstrated that blebbistatin can inhibit myofibroblast contractile forces and reduce collagen synthesis in vitro. Thus, the purpose of this study was to assess the use of blebbistatin in an animal model of elbow contracture, which was induced in 7 groups of 4 rats each (n = 28). All elbows were mechanically and histologically tested. The uninjured contralateral elbows of each rat were used as a control group. Capsule release surgery significantly improved (p < 0.01) outcomes 1 week after surgery compared to injury alone and was not significantly different from uninjured elbows. Three weeks after surgery, outcomes worsened, indicating joint stiffening consistent with what is observed clinically. The addition of blebbistatin did not significantly improve outcomes. Future work will investigate relationships among treatment, fibrotic tissue deposition, myofibroblast activity, and biomechanics to determine if blebbistatin is a useful adjunctive therapy for treating joint contracture.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615420 | PMC |
| http://dx.doi.org/10.1002/jor.25967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enteric Microcapsules Encapsulation of Roxithromycin-PVP Composite Core Particles to Inhibit Drug Crystallization upon Fluidized Bed Method for Oral Administration.
Chem Pharm Bull (Tokyo)
December 2024
School of Traditional Chinese Medicines, Shenyang Pharmaceutical University.
Enteric-coated microcapsules can protect roxithromycin (ROX) from acid hydrolysis enhancing efficacy, solubility, and dissolution rate, representing a promising oral formulation for children and patients with swallowing difficulties. ROX-layered core particles were obtained with polyvinylpyrrolidone (PVP) K30 as the binder and Eudragit L30 D-55 as the coating material using the Wurster process in a fluidized bed processor. The enteric-coated microcapsules were characterized using powder X-ray diffraction, differential scanning calorimetry, and polarized optical microscopy.
View Article and Find Full Text PDFA bimodal closed-loop neuromodulation implant integrated with ultraflexible probes to treat epilepsy.
Biosens Bioelectron
December 2024
2020 X-Lab, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, 200050, China; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, China; State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, 200050, China; School of Graduate Study, University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address:
Anti-seizure medications and deep brain stimulation are widely used therapies to treat seizures; however, both face limitations such as resistance and the unpredictable nature of seizures. Recent advancements, including responsive neural stimulation and on-demand drug release, have been developed to address these challenges. However, a gap remains, as electrical stimulation provides only transient effects while medication has a delayed onset.
View Article and Find Full Text PDFHairpin aptamer and ROS-sensitive microcapsule-mediated glycoprotein determination for the prognosis of colorectal cancer.
Mikrochim Acta
December 2024
State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang City and Guian New District, No.6 Ankang Avenue, Guizhou, 561113, China.
A novel glycoprotein assay was developed by integrating the hairpin aptamer (H-APT)-mediated glycoprotein recognition and the reactive oxygen species-sensitive microcapsule (ROS-MC)-induced signal amplification. The analyzing process begins with the transfer of the target glycoprotein to a chlorin e6 (Ce6)-labeled DNA sequence via H-APT-mediated DNA displacement. Subsequently, the Ce6-labeled DNA was used to induce the disassembly of fluorophore-loaded ROS-MC under 650-nm light irradiation.
View Article and Find Full Text PDFSupramolecular dextran/polyamine phosphate nanocapsules with smart responsiveness for encapsulation of therapeutics.
J Colloid Interface Sci
December 2024
Department of Chemistry 'Ugo Schiff', University of Florence, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy. Electronic address:
The polyallylamine hydrochloride (PAH) polymer is here functionalized with branched and biocompatible polysaccharide dextran (DEX) molecules. Covalent conjugation of DEX to PAH has been achieved through a straightforward reductive amination approach, allowing for a controlled number of DEX chains per PAH polymer (PAH:DEX, n = 0.1, 0.
View Article and Find Full Text PDFA rare case report of severe aplastic anaemia caused by long-term use of zidovudine.
BMC Infect Dis
December 2024
Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou, Zhejiang, China.
Background: Zidovudine is an antiviral drug used to treat acquired immune deficiency syndrome (AIDS). Anaemia is a common adverse effect of zidovudine that usually occurs in the first 2 to 4 weeks of initial treatment. Here, we describe a patient with HIV infection who developed severe aplastic anaemia 11 years after taking zidovudine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!